These changes were reverted in patients treated with rosiglitazone, leading Randriamboavonjy et al. [37] to suggest that rosiglitazone may contribute to a decrease in the development of vascular diseases associated with type 2 diabetes mellitus through actions on PECAM-1. Here, PECAM1 is linked to type 2 diabetes mellitus.